http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-048937-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D263-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-42 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-32 |
| filingDate | 2005-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_302d9feb2fc8840bb1ef36528415b889 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b353e57f75375da52bc4e9fe99348f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77bb4eac547a9ea554302544d53d9ed1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc8f87d526c3e7eeb0a5f09f64e48df5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2160683a685e0016f910b6cf1d37135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9cc00a8d75fac400cc6697576a961f2 |
| publicationDate | 2006-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-048937-A1 |
| titleOfInvention | PROCESS TO PREPARE ATAZANAVIR BISULFATE FORM E3 AND CONFIGURATION MATERIAL C |
| abstract | A process for preparing the HIV protease inhibitor, atazanavir bisulfate, wherein an atazanavir free base solution in an organic solvent is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the Free base, seeds of Atazanavir bisulfate Form A crystals are added to the reaction mixture, such as bisulfate form crystals, additional concentrated sulfuric acid is added in multiple stages at increased rates according to a cubic equation, to effect the formation of Form A crystals of atazanavir bisulfate. A process for preparing atazanavir bisulfate as a configuration material C with an X-ray spectrum is also provided, as shown in the figure. A new form of atazanavir bisulfate is also provided which is form E3 which is a highly crystalline triethanolate solvate of the ethanol bisulfate salt characterized by its X-ray spectrum, as shown in the figure. Pharmaceutical formulations comprising configuration material C, others comprising Form E3 or Form A of atazanavir bisulfate. |
| priorityDate | 2004-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.